(June 26, 2024, 12:41 PM EDT) -- LOS ANGELES — A federal judge in California transferred to a federal court in New York a putative class complaint brought by investors in a biotechnology company who say the company misled them by suggesting that its COVID-19 vaccine was still relevant despite not having approval from the Food and Drug Administration to target the most common subvariant at the time, after the parties stipulated to transfer the venue for the convenience of all involved....